New derivatives of imatinib with antimyeloproliferative activity

Vol. 1, 2019 - 108987
Poster only
Favorite this paper
How to cite this paper?
Abstract

Recently, many studies described tyrosine kinases as essential mediators of the signalling cascade, with significative roles in many biological processes, including the pathophysiology of cancer. The imatinib was the first inhibitor of Bcr-Abl tyrosine kinase (TKI) for the treatment of Chronic Myeloid Leukemia (CML) that showed activity against some cells of human lung cancer. Thus, the objective of this work is the synthesis and the antimyeloproliferative evaluation of ten new imatinib analogues. These compounds were designed from molecular hybridization between isatins and derivatives, used as TKI, with the phenylamino pyrimidine (PAP) skeleton, the significant pharmacophoric fragment of imatinib. The final products 1-2 (a-e) were synthesized with a high degree of purity and in moderate yields and were evaluated against K562 (CML cells) and A549 (lung cancer cells) lines. The results have shown that the derivatives were inactive in K562, but presented good activity for A549, being more active than imatinib.

Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
Chronic myeloid leukemia
lung cancer
tyrosine kinase inhibitors
imatinib
PAPP